CN107519199A - A kind of biological quantum low-frequency resonance solution for reducing blood viscosity - Google Patents
A kind of biological quantum low-frequency resonance solution for reducing blood viscosity Download PDFInfo
- Publication number
- CN107519199A CN107519199A CN201710790581.7A CN201710790581A CN107519199A CN 107519199 A CN107519199 A CN 107519199A CN 201710790581 A CN201710790581 A CN 201710790581A CN 107519199 A CN107519199 A CN 107519199A
- Authority
- CN
- China
- Prior art keywords
- parts
- frequency resonance
- biological
- blood viscosity
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title abstract description 41
- 239000008280 blood Substances 0.000 title abstract description 41
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 25
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 14
- 239000003124 biologic agent Substances 0.000 abstract description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract description 12
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 abstract description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract description 10
- 239000004327 boric acid Substances 0.000 abstract description 10
- WBTCZEPSIIFINA-MSFWTACDSA-J dipotassium;antimony(3+);(2r,3r)-2,3-dioxidobutanedioate;trihydrate Chemical compound O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O.[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O WBTCZEPSIIFINA-MSFWTACDSA-J 0.000 abstract description 10
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 abstract description 9
- 229910000464 lead oxide Inorganic materials 0.000 abstract description 9
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 7
- KBJMLQFLOWQJNF-UHFFFAOYSA-N nickel(ii) nitrate Chemical compound [Ni+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O KBJMLQFLOWQJNF-UHFFFAOYSA-N 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- 238000010189 synthetic method Methods 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 38
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 20
- 235000012239 silicon dioxide Nutrition 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 12
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 12
- 239000010453 quartz Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 9
- 229940011671 vitamin b6 Drugs 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000011726 vitamin B6 Substances 0.000 description 8
- 235000019158 vitamin B6 Nutrition 0.000 description 8
- 235000008708 Morus alba Nutrition 0.000 description 7
- 241000907663 Siproeta stelenes Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 241000218231 Moraceae Species 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 229910052759 nickel Inorganic materials 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000004579 marble Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 241000239226 Scorpiones Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 4
- 235000013717 Houttuynia Nutrition 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000019738 Limestone Nutrition 0.000 description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- 239000010975 amethyst Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000010437 gem Substances 0.000 description 3
- 229910001751 gemstone Inorganic materials 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000010977 jade Substances 0.000 description 3
- 239000006028 limestone Substances 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229910021532 Calcite Inorganic materials 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 241000237636 Pheretima Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052612 amphibole Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002460 anti-migrenic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000002895 emetic Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 108010070324 lumbrokinase Proteins 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 229910052758 niobium Inorganic materials 0.000 description 2
- 239000010955 niobium Substances 0.000 description 2
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- -1 paranitrophenol sodium salt Chemical class 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008151 pyridoxamine Nutrition 0.000 description 2
- 239000011699 pyridoxamine Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 229910000519 Ferrosilicon Inorganic materials 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- MJUBAJMTFPBLMX-UHFFFAOYSA-N O=[Si]=O.O[Si](O)(O)O Chemical compound O=[Si]=O.O[Si](O)(O)O MJUBAJMTFPBLMX-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000006004 Quartz sand Substances 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 229910052891 actinolite Inorganic materials 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001748 carbonate mineral Inorganic materials 0.000 description 1
- 210000003451 celiac plexus Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 229940089454 lauryl aldehyde Drugs 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052592 oxide mineral Inorganic materials 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011031 topaz Substances 0.000 description 1
- 229910052853 topaz Inorganic materials 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229910052889 tremolite Inorganic materials 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229910021489 α-quartz Inorganic materials 0.000 description 1
- 229910000500 β-quartz Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of biological quantum low-frequency resonance solution of the reduction blood viscosity prepared by the physics synthetic method of biological agent and quantum low-frequency resonance.The present invention is disclosed as a kind of biological quantum low-frequency resonance solution for reducing blood viscosity, includes the raw material of following mass parts：100 parts of water, 1.0 2.0 parts of potassium antimonyl tartrate, 1.5 2.0 parts of potassium chromium sulfate, 0.1 1.0 parts of lead oxide, 4.0 5.0 parts of boric acid, 1.0 2.0 parts of aluminum sulfate, 1.0 2.0 parts of nickel nitrate, 6.0 7.0 parts of iron oxide, 0.1 1.0 parts of calcium carbonate.The present invention has the function of the sticky cell of diluted blood by the solution after biological agent and quantum low-frequency resonance, suppress the growth of tumour cell, it can activate and repair impaired DNA cells, prevention and control cytometaplasia and cancer cell are formed, damaged cell diffusion and inhibitory activity virus can be suppressed, there is detoxicating, killing bacteria effect.
Description
Technical field
The present invention relates to a kind of solution, more particularly to a kind of biological quantum low-frequency resonance solution for reducing blood viscosity.
Background technology
It is thick that blood viscousness is also referred to as blood.Highly viscous mass formed by blood stasis is medically, the elderly is susceptible to suffer from, can be through hemorheology
Inspection is made a definite diagnosis.The principal element for influenceing blood viscosity has：Haemocyte sexual factor, such as haemocyte quantity, size, form,
Erythrocyte deformability, platelet function etc.；Blood plasma sexual factor, as plasma protein (particularly fibrinogen, immunoglobulin),
Blood glucose, blood fat, fibrinolytic etc.；Vasculogenic factor, such as length of vessel, diameter and inner membrance smoothness.The symptom of blood viscousness：
1. dizziness from morning, does not regain consciousness, the couchant 3. paroxysmal eye-blurreds of asthma of working of thought slowness 2..If blood becomes sticky, just
Capillary can be hurt, or even blocks capillary.Consequently, it is possible to just not exclusively oxygen and nutriment can not transport
Problem, the cell on periphery all can be dead.And loose blood vessel is easily absorbing fat, cholesterol, calcium etc., thus blood
It can become to be difficult to pass through all the more.Place if, gently may then cause headache, forgetful, shoulder is ached, pain in the back, oedema, long
Spot, long wrinkle, irregular menstruation, dysmenorrhoea, alopecia, insomnia, the problems such as trembled with fear；It is also possible to that arterial sclerosis can be accelerated, or even draws
Play the major disease such as cerebral infarction and miocardial infarction.
Therefore, in view of the above-mentioned problems, the present invention be provided with it is a kind of reduce blood viscosity biological quantum low-frequency resonance it is molten
Liquid.
The content of the invention
It is an object of the invention to provide a kind of biological quantum low-frequency resonance solution for reducing blood viscosity, the reduction blood
The solution of viscosity can improve blood viscousness disease symptoms.
The purpose of the present invention is achieved through the following technical solutions：A kind of biological quantum low frequency for reducing blood viscosity
Resonate solution, includes the raw material of following mass parts：100 parts of water, potassium antimonyl tartrate 1.0-2.0 parts, potassium chromium sulfate 1.5-2.0
Part, lead oxide 0.1-1.0 parts, boric acid 4.0-5.0 parts, aluminum sulfate 1.0-2.0 parts, nickel nitrate 1.0-2.0 parts, iron oxide 6.0-
7.0 parts, calcium carbonate 0.1-1.0 parts.
Further, the raw material of the biological quantum low-frequency resonance solution of the reduction blood viscosity includes following mass parts
Raw material：100 parts of water, potassium antimonyl tartrate 1.2-1.8 parts, potassium chromium sulfate 1.6-1.8 parts, lead oxide 0.4-0.9 parts, boric acid 4.2-
4.8 parts, aluminum sulfate 1.2-1.8 parts, nickel nitrate 1.2-1.8 parts, iron oxide 6.2-6.8 parts, calcium carbonate 0.2-0.8 parts.
Further, the raw material of the biological quantum low-frequency resonance solution of the reduction blood viscosity includes following mass parts
Raw material：100 parts of water, 1.3 parts of potassium antimonyl tartrate, 1.6 parts of potassium chromium sulfate, 0.4 part of lead oxide, 4.2 parts of boric acid, aluminum sulfate 1.2
Part, 1.6 parts of nickel nitrate, 6.2 parts of iron oxide, 0.3 part of calcium carbonate.
Further, the raw material of the biological quantum low-frequency resonance solution of the reduction blood viscosity is also including mass parts
0.1-4.0 parts silicate, 0.1-1.0 parts malachite and 5-30 part biological agents.
Further, the silicate is selected from quartz, agate, light jade, amethyst, yellow quartz, nephrite and greenstone or albumen
One kind in stone.
Further, the biological agent is made by earthworm, cordate houttuynia, mulberries, rock coptis root, scorpion and hoary hair are amiable and compliant.
Further, the raw material of the biological quantum low-frequency resonance solution of the reduction blood viscosity also includes 2- dimethyl propylenes
One of aldehyde, paracetamol, vitamin B6, Atlantic Ocean shell, metal niobium and metal osmium.
Further, the mass parts of the biological agent are 10-20 parts.
Further, the mass parts of the biological agent are 15 parts.
The present invention also provides the solution and is used to treat the sticky application of blood.
The present invention has the following advantages that compared with prior art：
The present invention has the function of the sticky cell of diluted blood by the solution after low-frequency resonance, suppresses the life of tumour cell
Long, capable of inhibiting cell and viral activity, has bactericidal action.
Hydrogen-rich quantum low-frequency resonance solution is drunk for a long time, the pernicious free radical of body can be removed, hydrogen-rich quantum low-frequency resonance is molten
Liquid, combine free radical into soma and form solution, exclude in vitro, it is molten to drink hydrogen-rich quantum low-frequency resonance by metabolism
Liquid energy effectively removes internal toxic free radicals and pernicious active oxygen, reduces health-physical fitness, is extremely easy to absorption enhancement metabolism,
Toxin-expelling and face nourishing anti-aging.
Embodiment
Technical scheme is clearly and completely described below in conjunction with embodiment, it is clear that described reality
It is part of the embodiment of the present invention to apply example, rather than whole embodiments.Based on the embodiment in the present invention, the common skill in this area
The every other embodiment that art personnel are obtained under the premise of creative work is not made, belong to the model that the present invention protects
Enclose.
The reduction blood prepared the present invention relates to a kind of physics synthetic method by biological agent and quantum low-frequency resonance glues
The biological quantum low-frequency resonance solution of denseness.
Potassium antimonyl tartrate semihydrate is also known as tartar emetic semihydrate, and molecular formula is C8H18K2O15Sb2, and molecular weight is
675.935, it is a kind of water white transparency crystalline solid or white particle powder, and medical industry is used as emetic and treatment snail fever
Injection.
The molecular formula of potassium chromium sulfate is CrK (SO4) 212H2O, relative molecular mass 499.Potassium chromium sulfate can be used for dividing
Analysis reagent, microscopic analysis fixative, prepare other chromic salts, mordant, photomechanical production, leather tanning, fiber waterproof, manufacture ink
Water, tanning agent, mordant and photograph fixer etc..
National pharmaceutical grade (NF) boric acid is used in cosmetics, amenities and medicine.It also mixes institute PH processed with borax and delayed
Rush solution.As crosslinking agent emulsified wax, bacteriostatic agent is also acted as.
Paracetamol, molecular formula C8H9NO2, usually white crystalline powder, there is antipyretic effect, for feeling
Emit fever, arthralgia, neuralgia, antimigraine, pain caused by cancer and postoperative analgesia etc..By paranitrophenol sodium salt through being reduced into p-aminophenol,
It is acylated again to be made.
Vitamin B6 (Vitamin B6) is also known as pyridoxine, and it includes pyridoxol, pyridoxal and pyridoxamine, in vivo with phosphorus
The form of acid esters is present, and is a kind of water soluble vitamin, meets light or alkali destructible, non-refractory.Name as vitamin within 1936
B6.Vitamin B6 is clear crystal, soluble in water and ethanol, and stable in acid solution, the destructible in alkali lye, pyridoxol is heat-resisting,
Pyridoxal and pyridoxamine non-refractory.Vitamin B6 in saccharomycete, liver, grain, meat, fish, egg, beans and peanut content compared with
It is more.The constituent of the internal some coenzyme of vitamin B6 behaviour, participates in a variety of metabolic responses, especially has with amino acid metabolism close
Cut relation.Clinically using the Vitamin B6 preparation preventing and treating vomiting of pregnancy and radiation sickness vomiting.
Calcium carbonate is a kind of inorganic compound, is commonly called as lime stone, lime stone, stone flour, marble, calcite, and chemical formula is
CaCO3, in neutrality, it is substantially insoluble in, is dissolved in acid.It is Common materials on the earth, be present in aragonite, calcite, chalk,
In the rocks such as limestone, marble, calcareous tufa.Also it is the main component of animal skeleton or shell.Calcium carbonate is important building
Material, industrial purposes are very wide.
Malachite is the carbonate mineral of cupric, and chemical composition is Cu2 (OH) 2CO3, CuO71.9%, CO219.9%,
H2O8.15%.Belong to monoclinic system.Crystal habit is often in the form of a column or needle-like, very rare, generally in cryptocrystal stalactitic, bulk, skin
Shelly, concretion forms and fibrous agrregate.Have concentric layered shell polysaccharide, fiber radial air structure.There are green, peacock green, dirty-green etc..Chang You
Line band, silky luster or glassy lustre, seemingly it is clear to opaque.Index of refraction 1.66-1.91, birefringence 0.25, pleochroism are
It is colourless-yellowish green-dark green.Hardness 3.5-4.5, density 3.54-4.1g/cm3.Crisp, the conchoidal to irregular columnar fracture of property.Meet salt
Acid reacts, and easily dissolves.
Quartz, refer generally to low quartz (alpha-quartz), be that a most wide mineral are distributed in quartzy race's mineral.The stone of broad sense
English also includes high quartz (β-quartz), coesite etc..Main component is SiO2, water white transparency, often containing a small amount of impurity component,
And it is changed into translucent or opaque crystal, quality is hard.Quartz is that a kind of physical property and chemical property are sufficiently stable
Mineral resources, the oxide mineral of crystal category trigonal system.Quartz wedge also known as silica, mainly produce quartz sand (also known as silica sand)
Raw material, and silica refractory and fire ferrosilicon raw material.
Agate is one kind of calcedony class mineral, is often mixed with the line banding block of opal and cryptocrystalline quartz, hardness
7-7.5 degree, proportion 2.65, color quite has levels.Have translucent or opaque.It is conventional to do jewelry or enjoy use.Ancient times accompany
Bury the agate ball of normal visible bunchiness in thing.Agate has an annulus striped of a variety of colors, quality much like crystal, it is fine and smooth without
Impurity, there is the gloss of glass, transparent or semitransparent more stratiforms are presented, each layer overlaps each other, and has ripple, concentric, mottled, stratiform
Etc. a variety of decorative patterns.Main component is silica, and stratification is often repeated due to replacing with hydrated silicon dioxide (silicic acid).Because of its folder
Miscellaneous oxidized metal, color can be from pole light colors so that dark-coloured.With salts such as iron, cobalt, nickel, appoint their naturally osmotics in silicic acid gel
In, can manually it be made " agate ".
Amethyst, chemical composition SiO2.Trigonal system, crystal are in hexagonal columnar, cylinder tool band, there is left-handed form and right shape, double
It is brilliant very universal.Hardness 7.Often containing irregular or wing shape gas-liquid two-phase inclusion in crystal.It is personal value highest one in crystal family
Member, because purple is presented containing Mn, Fe3+ in crystal polymorph body.Transparent, being observed under dichroic mirror has obvious pleochroism.
The main component of yellow quartz is silica, and hardness seven, the yellow quartz of Gem Grade is extremely rare, with crocus
For top grade.The vibration frequency of its energy influences the solar plexus of the mankind, belongs to reason body.Yellow quartz is referred to as crystal in jewel circle
Topaz, its color is from pale yellow, true yellow, orange, olive yellow to golden yellow.
Nephrite refers to that (such as tremolites, actinolite mineral series) some in amphibole have the silicate mine of jewel value
Thing.Tiny amphibole mineral crystal forms compact shape aggregate in fibrous weave in.Nephrite has many kinds, and color also has
A lot, the general quality of top grade nephrite is fine and smooth, good toughness, has greasy luster.
Opal is the hydrate of silica, composition SiO2nH2O, is amorphous structure, so without certain outer
Shape, fracture are conchoidal, and the mainly colloidal precipitation of silica is formed, if be deposited in organic remains, form " tree
Change beautiful "；It is deposited in conch remains, then forms " Luo Huayu ", spiral shellization jade is only referred to as spiral shell in the rare discovery in Hainan, locals at present
Fossil or Hai Yu, because rare numbers are extremely precious.
Ground dragon protein contains the Multiple components such as clostridiopetidase A, fibrinolysin, Lumbrokinase, nucleic acid, trace element, and its molecular weight exists
5000-10000, belong to short chain small-molecule substance, can smoothly enter capilary, the quick micro- bolt dissolved in capilary, improve
The function of offshoot circulation is established in microcirculation.Pheretima extract (including Lumbrokinase etc.) has to internal blood coagulation system and fibrinolytic system
There is wide influence, both can obviously reduce rat platelet adherence rate, thrombosis and dissolve internal thrombus, and can in extension body
Increase rat cerebral blood flow (CBF), reduce cerebral vascular resistance.Pheretima extract can also improve mouse red blood cell deformability, so as to improve
Hemorheological property and microcirculation disorder.
Cordate houttuynia can improve immunity, have antibacterial action, antivirus action, diuresis, radiation resistance, microorganism
Effect, antitumor action, antiinflammatory action；Contained decanoy acetaldehyde, lauryl aldehyde, methyl n nonyl ketone, fragrant ethene wherein in cordate houttuynia
And the volatile oil component such as quercitrin, cordarine, to staphylococcus aureus, staphylococcus albus, shigella dysenteriae, Pseudomonas aeruginosa,
Proteus, paracolon, Grain-positive bacillus etc. have certain inhibitory action, to staphylococcus aureus and white
Staphylococcus effect is stronger.Can be clinically used for treat pneumonia, lung abscess, chronic bronchitis, pertussis, pyogenic arthritis,
Dept. of dermatology's illness, chronic cervicitis, dysentery, mumps, habitual constipation, acute icterohepatitis, nephrotic syndrome,
Cat fever.
Mulberries have improvement skin (including scalp) blood supply, nutrition skin, make skin delicate and the effect such as black hair, and energy
Anti-aging.Mulberries are middle-aged and old be healthy and strong U.S. face, the good fruit of anti-aging and good medicine.Eyes can be alleviated with improving eyesight by often eating mulberry fruit
The dry and astringent symptom of fatigue.Mulberries have immunologic enhancement.Mulberries have effect of gain to spleen, have enhancing to make hemolytic reaction
With, can prevent human body artery hardening, skeletal joint hardening, enhance metabolism.It can promote the growth of erythrocyte, prevent
Neuroleptic Leukocytopenia, and there is auxiliary work(to illnesss such as treatment diabetes, anaemia, hypertension, high fat of blood, coronary heart disease, neurasthenia
Effect.Mulberries, which have, to promote the production of body fluid to quench thirst, promotes digestion, helps the effect such as defecation, and proper amount of edible can promote gastric secretion, stimulate enterocinesia
And release scorching.
Rock coptis root can clearing heat and detoxicating, dampness removing, analgesic hemostatic, cure mainly hepatitis, the erosion of mucous membrane in the oral cavity, pinkeye, mesh screen, dysentery, diarrhoea,
Stomachache, hemorrhoid hemorrhage.Medically find that it has special efficacy to liver disorders, be widely used in hepatitis, hepatic sclerosis, liver cancer
Treatment, and obtain unexpected special effect.Meadowrueleaf corydalis root has special efficacy to inflammation, while has the more of anti-hepatitis virus and liver protection
Weight effect, so handy applied to hepatitis cirrhosis, applied to liver cancer, also obtaining improves life quality, extends the life-span
Effect.Toxic side effect is not found through long-term use.
Scorpion can detoxify：The toxin to be deposited for a long time in cleaning body, promotes health；Scorpion can anti-inflammatory analgetic：Releive
Pain, reduce pain.Scorpion can treat burn, pertussis, perianal inflammation, mammary gland disease, tuberculous osteoarthropathy, chronic nettle
Rash, otitis media suppurative, antimigraine.
Embodiment 1
The low-frequency resonance solution of blood viscosity is reduced, takes the raw material of following weight proportions to be prepared (every part of 15g)：Water
100 parts, 1.3 parts of potassium antimonyl tartrate, 1.6 parts of potassium chromium sulfate, 0.4 part of lead oxide, 4.2 parts of boric acid, 1.2 parts of aluminum sulfate, nitric acid
1.6 parts of nickel, 6.2 parts of iron oxide, 0.3 part of calcium carbonate, 2.0 parts of quartz, 0.5 part of malachite, 15 parts of biological agent with to acetyl ammonia
0.2 part of base phenol.
Embodiment 2
The low-frequency resonance solution of blood viscosity is reduced, takes the raw material of following weight proportions to be prepared (every part of 15g)：Water
100 parts, 1.2 parts of potassium antimonyl tartrate, 1.8 parts of potassium chromium sulfate, 0.3 part of lead oxide, 4.8 parts of boric acid, 1.8 parts of aluminum sulfate, nitric acid
1.2 parts of nickel, 6.8 parts of iron oxide, 0.2 part of calcium carbonate, 0.5 part of agate, 0.1 part of malachite, 10 parts of biological agent and vitamin B6
0.5 part.
Embodiment 3
The low-frequency resonance solution of blood viscosity is reduced, takes the raw material of following weight proportions to be prepared (every part of 15g)：Water
100 parts, 1.0 parts of potassium antimonyl tartrate, 1.5 parts of potassium chromium sulfate, 0.1 part of lead oxide, 4.0 parts of boric acid, 1.0 parts of aluminum sulfate, nitric acid
1.0 parts of nickel, 6.0 parts of iron oxide, 0.1 part of calcium carbonate, 0.1 part of light jade, 1.0 parts of malachite, 20 parts of biological agent and the Atlantic Ocean
0.1 part of shell.
Embodiment 4
The low-frequency resonance solution of blood viscosity is reduced, takes the raw material of following weight proportions to be prepared (every part of 15g)：Water
100 parts, 2.0 parts of potassium antimonyl tartrate, 2.0 parts of potassium chromium sulfate, 1.0 parts of lead oxide, 5.0 parts of boric acid, 2.0 parts of aluminum sulfate, nitric acid
2.0 parts of nickel, 7.0 parts of iron oxide, 1.0 parts of calcium carbonate, 3.0 parts of amethyst, 0.8 part of malachite, 17 parts of biological agent and niobium metal 0.3
Part.
Embodiment 5
The low-frequency resonance solution of blood viscosity is reduced, takes the raw material of following weight proportions to be prepared (every part of 15g)：Water
100 parts, 1.3 parts of potassium antimonyl tartrate, 1.6 parts of potassium chromium sulfate, 0.8 part of lead oxide, 4.3 parts of boric acid, 1.7 parts of aluminum sulfate, nitric acid
1.6 parts of nickel, 6.3 parts of iron oxide, 0.3 part of calcium carbonate, 2.0 parts of yellow quartz, 0.6 part of malachite, 13 parts of biological agent and osmium metal
0.6 part.
Model case one：Mr. Li, 45 years old, the manager of certain company.May last year talks about business out with client, appearance headache,
Dizzy symptom, is originally thought as and overworks, and just allows driver that Mr. Li sends back home rest, prominent after morning is got up
Feel general weakness, toilet is gone to from bedroom, feel that mind is clear, neck is soft.Household sees its serious symptom, goes to hospital to examine immediately
Look into, clinical principium is diagnosed as blood viscosity.Because patient is not desired to receive drug therapy, seek medical advice then using dietotherapy.
The low-frequency resonance solution of embodiment 1 and early supper are taken with eating, using 10 days, the disease such as dizziness, headache, general weakness
Shape mitigates, and continues to take the solution of embodiment 1 20 days, and blood pressure recovers normal；Patient takes the low frequency of embodiment 1 and is total to all the time
Shake solution, resistance enhancing, and appetite is also cumulative.
Model case two：Zou XX, female, 40 years old, Yantai City.Symptom：Patient started to spit blood before 1 year, headache
Dizziness, the symptom such as uncomfortable in chest, symptom has taken a turn for the better after sitting up, and it is 180/130mmHg to look into its blood pressure, has hypertension symptom, recently
In the time of half a year, headache after suddenly feeling tired, without symptoms such as dizzy, weak, insomnias, before 3 months, appearance suddenly is had a headache, is weak
Symptom, midnight is always felt to have difficulty in breathing, and is above-mentioned illness caused by blood viscosity through hospital diagnosis.To examine the time：
On January 20th, 2013, the low-frequency resonance solution of embodiment 2 is taken under the suggestion of doctor.
The low-frequency resonance solution of embodiment 2 is taken, takes 50g every time, with early supper with eating, is eaten 3 days, dizzy disease uncomfortable in chest
Shape mitigates；Edible 10 days, the malaise symptoms such as dizzy, uncomfortable in chest disappeared, and symptom out of breath has taken a turn for the better during prostrate；Continue to take 10 days,
Malaise symptoms are wholly absent, and are had no side effect during use.
Experimental example purpose is to verify whether solution of the present invention has curative effect to treatment blood viscosity.From 2012
In January in January, 2014, totally 300 blood viscosity patient, average age are that 50 random divisions are administration group and control group.In reality
One week before testing, the health of patient is recorded, looks over patient body symptom daily, it is ensured that administration group and control group feelings
Condition is basically identical.Administration group eats the low-frequency resonance solution of this product embodiment 3 daily, and control group is taken other treatment blood and glued
The medicine (medicine of the conventional therapy blood viscosity such as nimodipine tablet, Reserpine, prazosin) of denseness checks patient's body daily
Body situation, makes a record.
Table 1
Table 2 takes blood viscosity situation of change after 1-5 of embodiment of the present invention low-frequency resonance solution
The detection project and result of the biological quantum low-frequency resonance solution of the present invention are as follows：
1.pH detections are according to CJ94-2005
Detecting instrument：PH meter pHS-3C, acid buret, spectrophotometer 722N
Testing result 7.4, limit value 6.0-8.5, low-frequency resonance solution of the invention are qualified
2. radioresistance is tested
Detection is according to GB6566-2001 radioactive material radionuclides limitations
Detection device：3013B radiacmeters
Detection method：(1) Site Detection is carried out to natural brown marble, stationary value is read after 1 minute.(2) will be natural
Brown marble is soaked in running water, and stationary value is read after 1 minute.(3) natural brown marble is soaked in the present invention's
Low-frequency resonance solution, stationary value is read after 1 minute.
3. viscosity
Detect foundation：GB10247-88 viscosity determining procedures
Testing result：0.0033*10-3
4. the determination test of total economic value
Detection method：
(1) inoxidizability standard curve is drawn by standard of 400 μ g/ml gallic acid standard liquid
Gallic acid standard liquid 0,0.1,0.2,0.3,0.4,0.5 is added in 2.5mlpH=6 phosphate buffer solutions,
0.6,0.7,0.8,0.9ml, with double distilled water polishing to 1ml, the 1ml1% potassium ferricyanides are added, mixture is in 50 DEG C of constant temperatures
Under, heat 20min.Rapidly cool down, add 2.5ml10% trichloroacetic acid, 3500 turns of centrifugation 10min.Take supernatant liquor
2.5ml, add the double distilled waters of 2.5ml, then add 0.5ml0.1% iron chloride, be well mixed, surveyed after standing 10min under wavelength 700nm
Absorbance A value.
(2) measure of sample inoxidizability
Extraction is centrifuged, supernatant is taken, according to the assay method of Specification Curve of Increasing, sequentially adds reagent, it is empty with reagent
Make reference in vain, absorbance is determined at 700nm with 1cm cuvettes, compares its antioxidation activity.
Testing result：
5. coliform is killed except rate is tested
Detect foundation：《Antibacterial fabric method for testing performance》FZ/T01021-92
Detection method：
(1) low-frequency resonance solution example is stirred, uniformly smeared on cotton, a diameter of 5cm is made after to be dried
Sterilization print, while common print is made with the common cotton cloth for not applying sample and is put into conical flask, in 103kpa after sealing
Sterilize 15min under pressure, standby.
(2) test organisms bacteria suspension is prepared respectively, it is standby.
(3) 1ml bacteria suspensions are uniformly inoculated with sterilized straw respectively on sterilization print and common print sample, are inoculated with it
Afterwards, fully vibration washing, after appropriate dilution, done bacterium culture with 100ml buffer solutions respectively with tilt-pour process and counted, detected it and connect
Touch the bacterium number of time.
(4) 1ml bacteria suspensions are uniformly inoculated with the sample that will be filled in addition in antibacterial print and common print triangular flask respectively,
Put after sealing in 37 DEG C of incubators, taken out after 48h immediately, doing bacterium culture according to step 3 counts, after its periodically culture on sample
Bacterium number.
In summary, hydrone generation technique is separated with quantum low-frequency resonance effect technology and hydrogen and oxygen electrolyzing, made common
The link structure of the hydrone of drinking water changes into linear molecule structure, and makes hydrogen molecule in water rich in high concentration and a small amount of
Oxygen molecule, so as to realize to human body delivery of supplemental oxygen power and energy make erythrocyte directly keep the skin wet with energy be cell exclude
Toxin and rubbish, improve human internal environment, conditioning and improved effect are produced to many diseases.
Finally it should be noted that：Various embodiments above is merely illustrative of the technical solution of the present invention, rather than its limitations；To the greatest extent
The present invention is described in detail with reference to foregoing embodiments for pipe, it will be understood by those within the art that：Its according to
The technical scheme described in foregoing embodiments can so be modified, either which part or all technical characteristic are entered
Row equivalent substitution；And these modifications or replacement, the essence of appropriate technical solution is departed from various embodiments of the present invention technology
The scope of scheme.
Claims (10)
1. a kind of biological quantum low-frequency resonance solution for reducing blood viscosity, it is characterised in that it includes following mass parts
Raw material：
100 parts of water, potassium antimonyl tartrate 1.0-2.0 parts, potassium chromium sulfate 1.5-2.0 parts, lead oxide 0.1-1.0 parts, boric acid 4.0-
5.0 parts, aluminum sulfate 1.0-2.0 parts, nickel nitrate 1.0-2.0 parts, iron oxide 6.0-7.0 parts, calcium carbonate 0.1-1.0 parts.
A kind of 2. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 1, it is characterised in that
It includes the raw material of following mass parts：
100 parts of water, potassium antimonyl tartrate 1.2-1.8 parts, potassium chromium sulfate 1.6-1.8 parts, lead oxide 0.4-0.9 parts, boric acid 4.2-
4.8 parts, aluminum sulfate 1.2-1.8 parts, nickel nitrate 1.2-1.8 parts, iron oxide 6.2-6.8 parts, calcium carbonate 0.2-0.8 parts.
A kind of 3. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 2, it is characterised in that
It includes the raw material of following mass parts：
100 parts of water, 1.3 parts of potassium antimonyl tartrate, 1.6 parts of potassium chromium sulfate, 0.4 part of lead oxide, 4.2 parts of boric acid, aluminum sulfate 1.2
Part, 1.6 parts of nickel nitrate, 6.2 parts of iron oxide, 0.3 part of calcium carbonate.
A kind of 4. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 1, it is characterised in that
It is 0.1-4.0 parts silicate, 0.1-1.0 parts malachite and 5-30 part biological agents also including mass parts.
A kind of 5. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 4, it is characterised in that
The one kind of the silicate in quartz, agate, light jade, amethyst, yellow quartz, nephrite and greenstone or opal.
A kind of 6. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 4, it is characterised in that
The biological agent is made by earthworm, cordate houttuynia, mulberries, rock coptis root, scorpion and hoary hair are amiable and compliant.
A kind of 7. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 4, it is characterised in that
Also include one of 2- dimethyl propionic aldehyde, paracetamol, vitamin B6, Atlantic Ocean shell, metal niobium and metal osmium.
A kind of 8. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 4, it is characterised in that
The mass parts of the biological agent are 10-20 parts.
A kind of 9. biological quantum low-frequency resonance solution for reducing blood viscosity according to claim 8, it is characterised in that
The mass parts of the biological agent are 15 parts.
10. the solution according to any one of claim 1-9 is used to treat the sticky application of blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710790581.7A CN107519199A (en) | 2017-09-05 | 2017-09-05 | A kind of biological quantum low-frequency resonance solution for reducing blood viscosity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710790581.7A CN107519199A (en) | 2017-09-05 | 2017-09-05 | A kind of biological quantum low-frequency resonance solution for reducing blood viscosity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107519199A true CN107519199A (en) | 2017-12-29 |
Family
ID=60683622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710790581.7A Pending CN107519199A (en) | 2017-09-05 | 2017-09-05 | A kind of biological quantum low-frequency resonance solution for reducing blood viscosity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519199A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288869A (en) * | 2018-11-16 | 2019-02-01 | 深圳市中玛生物科技有限公司 | A kind of disease-resistant solution of sub-health population cytotrophy |
-
2017
- 2017-09-05 CN CN201710790581.7A patent/CN107519199A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109288869A (en) * | 2018-11-16 | 2019-02-01 | 深圳市中玛生物科技有限公司 | A kind of disease-resistant solution of sub-health population cytotrophy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106927784A (en) | Jing Dezhen health pottery mud and the glaze of energy anion releasing | |
| CN104800132A (en) | Preparing method of clove compound mouthwash | |
| Wyllie | An investigation of the source of arsenic in a well water | |
| CN107519199A (en) | A kind of biological quantum low-frequency resonance solution for reducing blood viscosity | |
| CN1031779C (en) | Anti-inflammatory health preserved egg and preparation method thereof | |
| Chika et al. | Evaluation of antibacterial activity of the leave extracts of Buchholzia coriacea. | |
| CN106138282A (en) | A kind of refined even electuary and preparation method thereof for diabetes patient's regulating lipoid and reducing blood pressure | |
| CN101015345A (en) | Health-care food with hypoxia-resistant and immunity-enhancing functions and its preparing process | |
| KR100326847B1 (en) | ToothPaste Which Contains Nephrite Jade Powder And Process For Preparing Thereof | |
| CN106333962A (en) | Composition for increasing bone density | |
| CN104042790B (en) | A kind of pharmaceutical composition and its application for health care for the middle and old aged | |
| CN109223910A (en) | Anti- flu honeysuckle moxa stick preparation method and application | |
| CN105434216A (en) | Pudilan antibacterial and antipruritic shower gel and preparation method thereof | |
| Gomes et al. | Products based on clay, mud, and sand with interest for balneotherapy | |
| Smith et al. | H18 James Clark White: a pioneer of American dermatology | |
| CN103919132A (en) | Preparation method of ant powder containing ant polypeptides and chitosan | |
| KR0129551B1 (en) | Skim-adhesive containing nephrite jade powder | |
| TWI785854B (en) | A lactobacillus strain for producing hyaluronic acid, and an application and a composition thereof | |
| KR100310160B1 (en) | Bamboo Salt Which Contains Nephrite Jade Powder And Process For Preparing Thereof | |
| CN109793757A (en) | A kind of composition and its preparation method and application inhibiting cicatrix of skin growth | |
| CN101804073A (en) | Preparation method of pearl producing immune reinforcing agent | |
| Ruddock | The Homœopathic Vade Mecum of Modern Medicine and Surgery... Much Improved and Enlarged | |
| Fathima et al. | Preparation and Evaluation of Ginger Mouth Gargle | |
| Kebria et al. | The Trend of Epidemiological Changes of Brucellosis in the Period before and after the COVID-19 Pandemic in North of Iran (2015-2023). | |
| CN101069701B (en) | Ant-ganoderma particles and preparating method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171229 |
|
| RJ01 | Rejection of invention patent application after publication |